Pancreatic cancer has a dismal prognosis because most lesions are unresectable where as adjuvant and palliative chemotherapy exhibits poor results.
Introduction
Adenocarcinoma of the pancreas is a leading cause of cancer death worldwide and is increasing in prevalence in Japan (O'Connell, 1985; Gudjonsson, 1987; Micheli, Yancik, Krogh et al., 2002) . At the time of diagnosis, 80-90% of patients with pancreatic cancer have an advanced disease and less than one-fourth of tumors may be surgically removed (Martin, Weinerman, 1992; Link, Gansauge, Goerich et al., 1997; Tsuchiya. Tajima et al., 2001 ). Systemic chemotherapy is an alternative treatment for patients with advanced and unresectable pancreatic cancer and many clinical trials have been performed in an attempt to find the optimal anti-cancer drug regimen. The combination of 5-FU and leucovorin has been shown to have some anti-cancer effect in patients with advanced gastrointestinal and pancreatic cancer (Oman, Blind, Naredi et al., 2001; Huguier, Barrier, Valinas et al., 2001; Oettle, Arning, Pelzer et al., 2000; Andre, Balosso, Louvet et al., 2000; Kornek, Schratter-Sehn, Marczell et al., 2000) . However, the results for pancreatic cancer were far from satisfactory with a maximal response rate of 20-30% with either mono-or combination therapy. This pilot study was designed to examine the effect of the combination drug regime of 5-FU, leucovorin and MMC. Table I. In brief, criteria included patients with measurable disease, a life expectancy of at least 3 months, EOCG performance status<2, age of<80 years old, no significant central nerve system disease and no previous chemotherapy or radiotherapy. All patients were required to have normal hepatic, renal and bone marrow function. Six patients (four males and two females, mean age 60.7 years) matched the criteria and were enrolled in this study. Their profiles are summarized in Table II . All tumors were located in the head of the pancreas and had a mean diameter of 27.3mm before treatment was commenced. Five patients were judged to have unresectable tumors because of the involvement of large arteries such as the superior mesenteric artery or the common hepatic artery, and the remaining patient had lung metastases. Three patients received palliative surgery and two patients required endoscopic stenting for biliary decompression. 
Results
The effects of the chemotherapy were summarized in Table III and DU-PAN-2 dramatically fell just after the initiation of the treatment. The serum DU-PAN-2 level fell from 430U/ml to undetectable levels after two cycles whilst the serum CA19-9 level fell from 230U/ml to normal levels after four cycles. Decrease in tumor size was documented by CT scanning and estimated to be a partial response after 6 cycles whilst a complete response was observed after 12 cycles and has continued for 24 months (Figure 1 ). This patient received 12 cycles of the protocol drug regimen and a further 10 cycles without MMC. The complete response has continued for 36 months after the initial surgery. , 1996) , leucovorin (Oman, Blind, Naredi et al., 2001; Huguier, Barrier, Valinas et al., 2001; Oettle, Arning, Pelzer et al., 2000; Andre, Balosso, Louvet et al., 2000; Kornek, Schratter-Sehn, Marczell et al., 2000; Link, Formentini, Papachristov et al., 1997; Raderer, Kornek, Hejna et al., 1997) and interferons were used with 5-FU as biochemical modulators, and epirubicin (Raderer , Kornek, Hejna et al., 1997) , mitomycin, cyclophosphamide and many other agents were used in an attempt to gain synergistic effects . Weekly 5-FU with leucovorin, daily dipyridamole and intermittent mitomycin-C was reported to be effective palliative, neoadjuvant and adjuvant chemotherapy for pancreatic cancer Todd, Gloor, Lane et al., 1998) . Early survival analysis by Chakravarthy et al., suggested a trend toward increased median disease-free survival (8.3 vs. 17 months) using the same protocol as an adjuvant chemotherapy .
In the study of Burch et al., 9 partial responses and 1 complete tumor response were seen out of 46 evaluable patients of unresectable pancreatic cancer . Todd et al reported a 39% response rate, 14 partial responses and one complete response out of 38 cases of unresectable pancreatic cancer (Todd, Floor, Lane et al., 1998) .
Considering the encouraging results from the combination of anti-cancer drugs, we modified this chemotherapeutic protocol for pancreatic cancer and designed this pilot study.
Five of six patients died of their disease following a 4.4 month period of disease ANNALS OF Cancer Research and Therapy stabilization and a median survival of 8.9 months, which a promising result compared to other series for pancreatic cancer. Furthermore, one patient exhibited a complete response for more than 36 months documented by CT scanning, tumor markers and clinical manifestations. In previous series, maximal one-year survival rates were 10-20% and complete response and/or more than two-year survival was quite rare . In some clinical trials, some patients with unresectable pancreatic cancer were reported to show long-term survival although the overall response of the series was poor. It is unclear why some cases appear to be sensitive to chemotherapy, whereas others are unresponsive. As the responder in this study showed no special characteristics comparing to the other cases, the reason of the variable responses was also unclear. The characteristics of pancreatic cancer may be varied and individualized, hence chemotherapy should ideally be tailored to the individual patient based on the unique characteristics of the disease. The detection of potentially chemotherapy-responsive tumors would significantly improve the response rate of tumors and would facilitate the selection of effective individualized regimens. This is a most important area of research in the future.
In conclusion, the combination of 5-FU, leucovorin, and mitomycin-C is well tolerated and justifies future comparative clinical trials which should incorporate biochemical, histopathological and genetic techniques to examine why this drug regimen may be more effective in some patients. 
